Cerda-Cristerna BI, Garrocho-Rangel JA, Flores-Reyes HE, Pozos-Guillén AJ

Idioma: Español
Referencias bibliográficas: 51
Paginas: 6-11
Archivo PDF: 100.78 Kb.

RESUMEN

Las microesferas son sistemas de liberación controlada de medicamentos por lo que tienen un gran potencial de uso en diversos tratamientos en Estomatología. Las microesferas pueden elaborarse del co-polímero biodegradable ácido poli (láctico-coglicólico). En ellas pueden encapsularse y luego liberarse diferentes tipos de biomoléculas como antibióticos, analgésicos o proteínas. Por lo tanto, al mismo tiempo que las microesferas se degradan en los tejidos, ellas liberan por difusión las moléculas terapéuticas de manera controlada y durante un periodo de tiempo que puede ir desde horas hasta meses. Las microesferas pueden implantarse localmente sobre el sitio de una lesión, ya sea en el hueso mandibular o el órgano dentario, de tal forma que el medicamento es liberado directamente en el sitio de la lesión requiriendo muy bajas concentraciones terapéuticas. Por sus propiedades, las microesferas se han convertido en opciones atractivas para tratamientos de regeneración de tejidos, tratamientos antimicrobianos o bien tratamientos analgésicos. La presente revisión presenta los conceptos básicos sobre las microesferas, el polímero con el que se desarrollan así como sus aplicaciones y las perspectivas de uso en Estomatología.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Becker DE. Adverse drug interactions. Anest Progress 2011;58:31-41.

2. Swift JQ, Gulden WS. Antibiotic therapy--managing odontogenic infections. Dent Clin North Am 2002;46:623-633.

3. Nusstein JM, Reader A, Drum M. Local anesthesia strategies for the patient with a "hot" tooth. Dent Clin North Am 2010;54:237-247.

4. Khojasteh SC, Wong H, Hop CECA. Pharmacokinetics Drug Metabolism and Pharmacokinetics Quick Guide. In.: Springer New York; 2011. p. 1-15.

5. Blanton PL, Jeske AH. Dental local anesthetics: alternative delivery methods. J Am Dent Assoc 2003;134:228-234.

6. Newbrun E. Topical fluorides in caries prevention and management: a North American perspective. J Dent Edu 2001;65:1078-1083.

7. Paula VA, Modesto A, Santos KR, Gleiser R. Antimicrobial effects of the combination of chlorhexidine and xylitol. Br Dent J 2010;209:E19.

8. Jain KK. Drug Delivery Systems - An Overview Drug Delivery Systems. In: Jain KK, editor.: Humana Press; 2008. p. 1-50.

9. Langer R. Drug delivery. Drugs on target. Science 2001;293:58-59.

10. Carr MP, Horton JE. Evaluation of a transoral delivery system for topical anesthesia. J Am Dent Assoc 2001;132:1714-1719.

11. Henke CJ, Villa KF, Aichelmann-Reidy ME, Armitage GC, Eber RM, Genco RJ, et al. An economic evaluation of a chlorhexidine chip for treating chronic periodontitis: the CHIP (chlorhexidine in periodontitis) study. J Am Dent Assoc 2001;132:1557-1569.

12. Mundargi RC, Babu VR, Rangaswamy V, Patel P, Aminabhavi TM. Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives. J Control Release 2008;125:193-209.

13. Freiberg S, Zhu XX. Polymer microspheres for controlled drug release. Int J Pharm 2004;282:1-18.

14. Shive MS, Anderson JM. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Del Rev 1997;28:5-24.

15. Fredenberg S, Wahlgren M, Reslow M, Axelsson A. The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems--a review. Int J Pharm2011;415:34-52.

16. Freitas S, Merkle HP, Gander B. Microencapsulation by solvent extraction/evaporation: reviewing the state of the art of microsphere preparation process technology. J Control Release 2005;102:313-332.

17. Moioli EK, Clark PA, Xin X, Lal S, Mao JJ. Matrices and scaffolds for drug delivery in dental, oral and craniofacial tissue engineering. Adv Drug Deliv Rev 2007;59:308-324.

18. Nakashima M, Akamine A. The application of tissue engineering to regeneration of pulp and dentin in endodontics. J Endod 2005;31:711-718.

19. Sinha VR, Trehan A. Biodegradable microspheres for protein delivery. J Control Release 2003;90:261-280.

20. Rosa V, Della Bona A, Cavalcanti BN, Nor JE. Tissue engineering: from research to dental clinics. Dent Materials 2012;28:341-348.

21. Murray PE, Garcia-Godoy F, Hargreaves KM. Regenerative endodontics: a review of current status and a call for action. J Endod 2007;33:377-390.

22. Sykaras N, Opperman LA. Bone morphogenetic proteins (BMPs): how do they function and what can they offer the clinician? J Oral Science 2003;45:57-73.

23. Woo BH, Fink BF, Page R, Schrier JA, Jo YW, Jiang G, et al. Enhancement of bone growth by sustained delivery of recombinant human bone morphogenetic protein-2 in a polymeric matrix. Pharm Res 2001;18:1747-1753.

24. Alpaslan C, Irie K, Takahashi K, Ohashi N, Sakai H, Nakajima T, et al. Long-term evaluation of recombinant human bone morphogenetic protein-2 induced bone formation with a biologic and synthetic delivery system. Br J Oral Maxillofac Surg 1996;34:414- 418.

25. Phillips FM, Turner AS, Seim HB, 3rd, MacLeay J, Toth CA, Pierce AR, et al. In vivo BMP-7 (OP-1) enhancement of osteoporotic vertebral bodies in an ovine model. Spine J 2006;6:500-506.

26. Polak SJ, Levengood SK, Wheeler MB, Maki AJ, Clark SG, Johnson AJ. Analysis of the roles of microporosity and BMP-2 on multiple measures of bone regeneration and healing in calcium phosphate scaffolds. Acta Biomater 2011;7:1760-1771.

27. Samdancioglu S, Calis S, Sumnu M, Atilla Hincal A. Formulation and in vitro evaluation of bisphosphonate loaded microspheres for implantation in osteolysis. Drug Develop Ind Pharm2006;32:473-481.

28. Shi X, Wang Y, Ren L, Gong Y, Wang DA. Enhancing alendronate release from a novel PLGA/hydroxyapatite microspheric system for bone repairing applications. Pharm Res 2009;26:422-430.

29. Borromeo GL, Tsao CE, Darby IB, Ebeling PR. A review of the clinical implications of bisphosphonates in dentistry. Aust Dent J 2011;56:2-9.

30. Nakashima M. Bone morphogenetic proteins in dentin regeneration for potential use in endodontic therapy. Cytok Growth Factor Rev 2005;16:369-376.

31. Huang GT. Pulp and dentin tissue engineering and regeneration: current progress. Reg Med 2009;4:697-707.

32. Yang X, Zhang S, Pang X, Fan M. Mineralized tissue formation by bone morphogenetic protein-7-transfected pulp stem cells. J Endod 2012;38:170-176.

33. Helder MN, Karg H, Bervoets TJ, Vukicevic S, Burger EH, D'Souza RN, et al. Bone morphogenetic protein-7 (osteogenic protein-1, OP-1) and tooth development. J Dent Res 1998;77:545-554.

34. Mohammadi Z, Dummer PM. Properties and applications of calcium hydroxide in endodontics and dental traumatology. Int Endod J 2011;44:697-730.

35. Hunter AR, Kirk EE, Robinson DH, Kardos TB. In vitro characterization of poly(ethylene) glycol calcium citrate microspheres as a delivery system for the study of reparative dentinogenesis. Endod Dent Traumatol 1998;14:159-162.

36. Hunter AR, Kirk EE, Robinson DH, Kardos TB. A slow release calcium delivery system for the study of reparative dentine formation. Endod Dent Traumatol 1998;14:112-118.

37. Gopinath V, Ramakrishnan T, Emmadi P, Ambalavanan N, Mammen B, Vijayalakshmi. Effect of a controlled release device containing minocycline microspheres on the treatment of chronic periodontitis: A comparative study. J Indian Soc Periodontol 2009;13:79-84.

38. Hellström M-K, McClain PK, Schallhorn RG, Bellis L, Hanlon AL, Ramberg P. Local minocycline as an adjunct to surgical therapy in moderate to severe, chronic periodontitis. J Clin Periodontol 2008;35:525-531.

39. Renvert S, Lessem J, Dahlen G, Renvert H, Lindahl C. Mechanical and repeated antimicrobial therapy using a local drug delivery system in the treatment of peri-implantitis: a randomized clinical trial. J Periodontol 2008;79:836-844.

40. Stavropoulos MF, Shugars DA, Phillips C, Conrad SM, Fleuchaus PT, White RP, Jr. Impact of topical minocycline with third molar surgery on clinical recovery and health-related quality of life outcomes. J Oral Maxillofac Surg 2006;64:1059-1065.

41. Javed S, Kohli K. Local delivery of minocycline hydrochloride: a therapeutic paradigm in periodontal diseases. Curr Drug Deliv 2010;7:398-406.

42. Schar D, Ramseier CA, Eick S, Arweiler NB, Sculean A, Salvi GE. Anti-infective therapy of peri-implantitis with adjunctive local drug delivery or photodynamic therapy: six-month outcomes of a prospective randomized clinical trial. Clin Oral Implants Res 2012 May 9 doi:10.11117j.1600-0501.2012.02494.x.

43. Henry MA, Hargreaves KM. Peripheral mechanisms of odontogenic pain. Dent Clin North Am 2007;51:19-44.

44. Poveda Roda R, Bagan JV, Jimenez Soriano Y, Gallud Romero L. Use of nonsteroidal antiinflammatory drugs in dental practice. A review. Med Oral Patol Oral Cirugia Bucal 2007;12:E10-18.

45. Botting RM. Inhibitors of cyclooxygenases: mechanisms, selectivity and uses. J Physiol Pharma 2006;57 Suppl 5:113-124.

46. Hargreaves K, Abbott PV. Drugs for pain management in dentistry. Aust Dent J 2005;50:S14-22.

47. Castelli F, Conti B, Maccarrone DE, Conte U, Puglisi G. Comparative study of `in vitro' release of anti-inflammatory drugs from pol yl a ctide-co-gl ycol ide mi crospheres. Int J Pharm1998;176:85-98.

48. Fernández-Carballido A, Herrero-Vanrell R, Molina-Martiìnez IT, Pastoriza P. Biodegradable ibuprofen-loaded PLGA microspheres for intraarticular administration: Effect of Labrafil addition on release in vitro. Int J Pharm 2004;279:33-41.

49. Ricci M, Blasi P, Giovagnoli S, Rossi C, Macchiarulo G, Luca G, Basta G, Calafiore R. Ketoprofen controlled release from composite microcapsules for cell encapsulation: effect on posttransplant acute inflammation. J Control Release 2005;107:395-407.

50. Tuncay M, Calis S, Kas HS, Ercan MT, Peksoy I, Hincal AA. Diclofenac sodium incorporated PLGA (50:50) microspheres: formulation considerations and in vitro/in vivo evaluation. Int J Pharm2000;195:179-188.

51. Daniel NG, Goulet J, Bergeron M, Paquin R, Landry PE. Antiplatelet drugs: is there a surgical risk? J Can Dent Assoc 2002;68:683-687.